Lilly's $23 Billion Quarter: How the GLP-1 Empire Is Rewriting the Rules of Pharma
There is a number that defines what Eli Lilly just reported: 48. That is how many percent the company's revenue grew in the second quarter of 2026 compared to a year earlier - a rate of expansion that would be remarkable for a startup, and that is genuinely extraordinary for a 150-year-old pharmaceutical giant with a market capitalization north of $1 trillion.
Lilly reported Q2 2026 revenue of $22.97 billion against analyst expectations of $20.73 billion. Adjusted earnings per share came in at $8.38, against a consensus estimate of $6.01 - a beat of nearly 40%. The company raised its full-year 2026 revenue guidance to between $85 billion and $87 billion, up from the prior range of $82 billion to $85 billion. CEO Dave Ricks, speaking on CNBC's Squawk Box, put it plainly: "It's a really strong start to the year for Lilly... it's hard to think of a time that we've been in a better position than this."
That is not a boast. It is a description of a company that has, in the span of roughly three years, transformed itself from a respected but conventional pharmaceutical company into the dominant force in what may be the most consequential drug category of the decade.
The Numbers Behind the Numbers
The engine driving all of this is tirzepatide - the molecule that Lilly sells as Mounjaro for Type 2 diabetes and as Zepbound for obesity. Mounjaro's worldwide revenue rose 91% to $9.94 billion in the second quarter, including $4.8 billion in US sales and a remarkable $5.2 billion internationally. That international figure reflects a 172% surge in sales outside the United States - driven in part by Mounjaro's inclusion on China's national reimbursement formulary for Type 2 diabetes, which dramatically expanded access in the world's most populous country.
Zepbound, the obesity-specific formulation, posted $4.93 billion in revenue for the quarter, up 46% year-over-year. Combined, Mounjaro and Zepbound generated $14.9 billion in revenue in a single quarter - contributing $6.3 billion of growth compared to Q2 2025. To put that in context: $14.9 billion in quarterly revenue from two drugs that did not exist in commercial form four years ago.
The quarter also marked the first earnings report to include sales of Foundayo, Lilly's newly launched obesity pill, which received US approval in April. Foundayo generated $98 million in its first partial quarter of sales - a modest number that understates the strategic significance. Ricks noted that prescriptions for Foundayo have doubled month-over-month and that roughly a quarter of new patients starting on oral obesity medications are choosing Lilly's pill. The oral GLP-1 market is still in its earliest innings, and Lilly is already competing effectively against Novo Nordisk's Wegovy pill, which launched a few months earlier.
The Medicare Catalyst Nobody Is Fully Pricing In
The most underappreciated element of Lilly's second-half story is not in the Q2 numbers - it is in what started on July 1. That is when the Medicare GLP-1 Bridge program launched, making Lilly's obesity medicines available to eligible Medicare Part D patients for a $50 monthly copay. Lilly estimates that approximately 20 million Medicare patients may meet clinical criteria for obesity medicines. Two in five US adults aged 65 and older are living with obesity. Until July 1, virtually none of them had meaningful insurance coverage for GLP-1 drugs.
The rollout is early, but Ricks described it as "off to a strong start." The structural implication is significant: Lilly is entering the second half of 2026 with a new, large, and previously untapped patient population gaining access to its drugs for the first time. The Medicare tailwind has not yet shown up in the revenue line in any meaningful way. It will.
Lilly currently holds 60.9% of the US obesity and diabetes drug market, compared to Novo Nordisk's 38.8%. That market share figure is not static - it has been expanding as Mounjaro's clinical profile, which shows superior weight loss outcomes compared to semaglutide in head-to-head trials, continues to drive prescriber preference. The oral market adds a new dimension to the competition, but Ricks was explicit that Foundayo is "expansionary, not cannibalizing Zepbound" - meaning the pill is bringing new patients into the GLP-1 ecosystem rather than simply substituting for the injectable.
The M&A Machine Running on GLP-1 Cash
What Lilly is doing with its extraordinary cash generation is as interesting as the cash generation itself. The company is executing what Ricks has described as a historic acquisition spree, funded almost entirely by the GLP-1 windfall. In July, Lilly struck a deal to acquire a psychedelics drugmaker for $2.8 billion. In May, it announced plans to purchase three vaccine makers. The company is using its dominant position in metabolic disease to buy optionality in adjacent therapeutic areas - mental health, infectious disease, oncology - that could sustain growth well beyond the GLP-1 cycle.
This is a deliberate and rational strategy. The GLP-1 market will not remain a duopoly forever. Amgen, Pfizer, Roche, and a cohort of biotech companies are all advancing competing molecules. Lilly's management team is acutely aware that the window of maximum pricing power and market share is finite, and they are deploying the resulting cash flows to build a pipeline that does not depend on tirzepatide alone.
What the Broader Market Is Missing
Lilly's Q2 results landed in a market that has been preoccupied with AI infrastructure spending, geopolitical risk, and Federal Reserve policy. The stock rose roughly 4% to 5% on the day of the report - a solid move, but one that arguably understates the magnitude of what the company delivered. An EPS beat of nearly 40% against consensus is not a routine outperformance. It is a signal that the models analysts are using to forecast Lilly's business are still systematically underestimating the pace of GLP-1 adoption globally.
The international story is particularly underappreciated. Mounjaro's 172% international revenue growth reflects a drug that is penetrating large middle-income markets - Brazil, China, India - where patients are paying out of pocket at significant scale. Ricks noted that demand in these markets is "very strong and durable." As Lilly expands manufacturing capacity and regulatory approvals in additional countries, the international revenue line has the potential to become as large as the domestic one.
The GLP-1 revolution is not a US story anymore. It is a global one. And Eli Lilly, with 60.9% market share, a newly launched oral option, a Medicare tailwind just beginning to build, and a management team deploying cash flows into the next generation of drugs, is positioned at the center of it. The $23 billion quarter is not the peak. It is the baseline from which the next chapter begins.
